Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01271803
Other study ID # NO25395
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date February 17, 2011
Est. completion date December 12, 2017

Study information

Verified date July 2019
Source Hoffmann-La Roche
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This open-label, dose-escalation study of vemurafenib in combination with cobimetinib will evaluate the safety, tolerability and pharmacokinetics in participants with BRAFV600 mutation-positive metastatic melanoma. Participants with previously untreated, BRAFV600E mutation-positive, locally advanced/unresectable or metastatic melanoma or those who have progressed on vemurafenib monotherapy immediately prior to enrolling in this trial are eligible. Participants will be assigned to different cohorts with escalating oral doses of vemurafenib and cobimetinib. This study consists of 2 stages, Stage 1 (Dose Escalation Stage [DES] and Cohort Expansion Stage [CES]) and the anticipated time on study treatment is until disease progression, unacceptable toxicity or any other discontinuation criterion is met.


Recruitment information / eligibility

Status Completed
Enrollment 131
Est. completion date December 12, 2017
Est. primary completion date October 1, 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Participants with histologically confirmed melanoma (unresectable Stage IIIc and Stage IV metastatic melanoma, as defined by American Joint Committee on Cancer [AJCC])

- Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V) 1.1

- Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to (</=) 1

- Participants must

1. be previously untreated for locally advanced/unresectable or metastatic melanoma or

2. previously treated but without prior exposure to any BRAF or MEK inhibitor therapy or

3. progressed on vemurafenib while participating in a Phase I (including clinical pharmacology studies), II, or III clinical study or expanded access programs (EAP) immediately prior to enrollment in this study or

4. progressed on vemurafenib administered in a postmarketing setting immediately prior to enrollment in this study.

- Life expectancy >/=12 weeks

Exclusion Criteria:

- History of prior significant toxicity from another RAF or MEK pathway inhibitor requiring discontinuation of treatment

- Palliative radiotherapy within 2 weeks prior to first dose of study drug treatment

- Experimental therapy within 4 weeks prior to first dose of study drug treatment except vemurafenib

- Major surgery within 4 weeks of first dose of study drug treatment or planning a major surgery during the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cobimetinib
Participants will receive cobimetinib 60 to 100 mg at any of the 3 dosing schedules with or without vemurafenib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
vemurafenib
Participants will receive vemurafenib 720 or 960 mg along with cobimetinib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.

Locations

Country Name City State
Australia Peter Maccallum Cancer Institute; Medical Oncology Melbourne Victoria
United States University of Colorado; Anschutz Cancer Pavilion Aurora Colorado
United States University of Chicago Chicago Illinois
United States Karmanos Cancer Inst. ; Hudson Webber; Cancer Research Building Detroit Michigan
United States Indiana University - Department of Medicine, Division of Gastroenterology/Hepatology Indianapolis Indiana
United States UCLA Department of Medicine Los Angeles California
United States Vanderbilt University Medical Center Nashville Tennessee
United States New York University Medical Center New York New York
United States University of California at San Francisco San Francisco California
United States The Angeles Clinic and Research Institute, Santa Monica Office Santa Monica California

Sponsors (1)

Lead Sponsor Collaborator
Hoffmann-La Roche

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Dose-Limiting Toxicities (DLTs) During DES in Combination Cohorts DLT is defined as 1 of the following toxicities considered by the investigator to be related to study treatment: a) Grade 3 nausea, vomiting or diarrhea that resolved to Grade less than or equal to (=) 1 within 7 days, b) Grade 3 rash or photosensitivity that resolved to Grade =2 within 7 days, c) Grade 3 cutaneous squamous cell carcinoma (cuSCC) that was subsequently resected, d) Grade greater than or equal to (=) 3 fatigue or hyperuricemia that resolved to Grade =2 within 7 days, e) Grade 3 fever, f) Grade 3 or 4 elevation of serum creatine phosphokinase (CPK) levels, which is asymptomatic, deemed by the investigator to be clinically insignificant and that returned to Grade =2 during the 14-day cobimetinib treatment holiday, g) Grade =3 febrile neutropenia, h) Grade =4 neutropenia (absolute neutrophil count [ANC] less than <500/microliter [µL]), i) Grade =4 thrombocytopenia, j) Grade =4 anemia, k) Grade =3 elevation of total bilirubin, hepatic transaminase or alkaline phosphatase. 28 Days
Primary Maximum Tolerated Doses (MTD) of Vemurafenib and Cobimetinib When Administered in Combination in DES The highest dose level(s) at which fewer than one-third of participants experienced a DLT was declared the MTD. DLT is defined as 1 of the following toxicities considered by the investigator to be related to study treatment: a) Grade 3 nausea, vomiting or diarrhea that resolved to Grade =1 within 7 days, b) Grade 3 rash/photosensitivity that resolved to Grade =2 within 7 days, c) Grade 3 cuSCC that was subsequently resected, d) Grade =3 fatigue/hyperuricemia that resolved to Grade =2 within 7 days, e) Grade 3 fever, f) Grade 3 or 4 elevation of serum CPK levels, which is asymptomatic, deemed to be clinically insignificant and returns to Grade =2 during the 14-day cobimetinib treatment holiday, g) Grade =3 febrile neutropenia, h) Grade =4 neutropenia (ANC <500/ µL), i) Grade =4 thrombocytopenia, j) Grade =4 anemia, k) Grade =3 elevation of total bilirubin, hepatic transaminase or alkaline phosphatase. 28 Days
Primary Maximum Plasma Concentration (Cmax) of Cobimetinib on Day 1, Cycle 1 Cycle 1: predose (0 hours [hr]) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Primary Cmax of Cobimetinib on Day 1, Cycle 1 in Cohort 3 Cycle 1: predose (0 hr) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Primary Time Taken to Reach Maximum Plasma Concentration (Tmax) of Cobimetinib on Day 1, Cycle 1 Cycle 1: predose (0 hr) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Primary Area Under Concentration Versus Time Curve (AUC) Over a Period of 24 Hours (AUC0-24) of Cobimetinib on Day 1, Cycle 1 Cycle 1: predose (0 hr) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Primary AUC0-24 of Cobimetinib on Day 1, Cycle 1 of Cohort 3 Cycle 1: predose (0 hr) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Primary Cmax of Cobimetinib on Day 14 (Steady State), Cycle 1 Cycle 1: predose (0 hr) on Days 8, 14; 0.5, 1, 2, 4, 6 hr postdose on Day 14
Primary Tmax of Cobimetinib on Day 14 (Steady State), Cycle 1 Cycle 1: predose (0 hr) on Days 8, 14; 0.5, 1, 2, 4, 6 hr postdose on Day 14
Primary AUC0-24 of Cobimetinib on Day 14, Cycle 1 Cycle 1: predose (0 hr) on Days 8, 14; 0.5, 1, 2, 4, 6 hr postdose on Day 14
Primary Clearance (CL) of Cobimetinib on Day 14 (Steady State), Cycle 1 Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Cycle 1: predose (0 hr) on Days 8, 14; 0.5, 1, 2, 4, 6 hr postdose on Day 14
Primary Cmax of Vemurafenib on Day -1, Cycle 1 in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study Predose (0 hr) on Days -1, 1; 2, 4, 6, 8 hr postdose on Day -1
Primary Cmax of Vemurafenib on Day -1, Cycle 1 of Cohorts 1C and 2A in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study Predose (0 hr) on Day -1, 1; 2, 4, 6, 8 hr postdose on Day -1
Primary Tmax of Vemurafenib on Day -1, Cycle 1 in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study Predose (0 hr) on Day -1, 1; 2, 4, 6, 8 hr postdose on Day -1
Primary Cmax of Vemurafenib on Day 1, Cycle 1 in BRAFi-naïve Participants Predose (0 hr) on Day 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Primary Cmax of Vemurafenib on Day 1, Cycle 1 in Cohort 1A in BRAFi-naïve Participants Predose (0 hr) on Day 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Primary Tmax of Vemurafenib on Day 1, Cycle 1 in BRAFi-naïve Participants Predose (0 hr) on Day 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Primary Cmax of Vemurafenib on Day 14, Cycle 1 Predose (0 hr) on Days 14, 15; 0.5, 1, 2, 4, 6, 8 hr postdose on Day 14
Primary Tmax of Vemurafenib on Day 14, Cycle 1 Predose (0 hr) on Days 14, 15; 0.5, 1, 2, 4, 6, 8 hr postdose on Day 14
Secondary Percentage of Participants With an Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (V) 1.1 Tumor response of CR or PR is considered as objective response. CR: disappearance of all target lesions, reduction in short axis <10 millimeters in pathological lymph nodes (target and non-target lesions); PR: at least a 30 percent (%) decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Responses were confirmed by repeat assessments =4 weeks after initial documentation. Assessed at screening (within 28 days prior to initiation of Cycle 1), every 6 weeks thereafter until disease progression (up to 82 months)
Secondary Percentage of Participants With Disease Progression According to RECIST V 1.1 Progressive disease (PD) according to RECIST V 1.1: at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (nadir), including baseline; in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm; appearance of 1 or more lesions is also considered as progression. Assessed at screening (within 28 days prior to initiation of Cycle 1), every 6 weeks thereafter until disease progression or death (up to 82 months)
Secondary Median Duration of Response (DOR) Duration of response, defined as the time from first occurrence of a documented objective response until the time of disease progression, as determined by investigator review of tumor assessments using RECIST v 1.1, or death from any cause during the study (that is within 30 days after the last dose of study treatment). Time from first occurrence of objective response until the time of disease progression or death from any cause (up to 82 months)
Secondary Overall Survival (OS) OS was defined as the time from the date of randomization to the date of death due to any cause. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up. OS analyzed using Kaplan-Meier estimate. Assessed at screening (within 28 days prior to initiation of Cycle 1), every 6 weeks thereafter until disease progression or death (up to 82 months)
Secondary Average Percent Change From Baseline in Fluorodeoxyglucose-positron Emission Tomography (FDG-PET) at Cycle 1 and Cycle 2 The pharmacodynamic effect of cobimetinib in combination with vemurafenib was assessed by measuring changes in FDG uptake as characterized by the lean body mass corrected (LBM) maximum standardized uptake value (SUV max) measurement using FDG-PET. Post-baseline timepoint Cycle 1 was averaged between Days 10 to 14 and Cycle 2 for Days 14+7. Cycle 1 (Days 10 to 14), Cycle 2 (Days 14+7)
Secondary Pharmacodynamics: Number of Participants With Mitogen-Activated Protein Kinase (MAPK) Inhibition, as Assessed by Immunohistochemistry (IHC) Changes in effector molecules of the MAPK pathway that are directly or indirectly affected by BRAF and MEK inhibition (including but not limited to ERK and phosphorylated ERK and MEK) by IHC using biopsies at baseline, between Days 10-14 of Cycle 1, and at disease progression. IHC is a staining process performed on fresh/frozen tumor tissue samples. At baseline; Cycle 1: Day 14; at disease progression (Up to 32 months)
See also
  Status Clinical Trial Phase
Completed NCT04229277 - Fast Track Diagnosis of Skin Cancer by Advanced Imaging N/A
Completed NCT03653819 - High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs N/A
Active, not recruiting NCT04074096 - Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis Phase 2
Completed NCT02935790 - Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab Phase 1
Recruiting NCT05478876 - Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract N/A
Completed NCT01211262 - Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma Phase 1
Recruiting NCT03649529 - Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy Early Phase 1
Completed NCT03278665 - 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy Phase 1/Phase 2
Completed NCT04452214 - A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Completed NCT01455259 - Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors Phase 1/Phase 2
Completed NCT00978913 - Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma Phase 1
Completed NCT00232726 - Clinical Study of Previously Untreated Patients With Malignant Melanoma Phase 2
Completed NCT00336986 - Efficacy Study of IL-21 to Treat Metastatic Melanoma Phase 2
Completed NCT00350597 - GM-CSF as Adjuvant Therapy of Melanoma Phase 2
Completed NCT02523313 - Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED Phase 2
Completed NCT03545334 - Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study N/A
Completed NCT04253574 - Comparison of PET/CT and Ultrasound in Staging of Malignant Melanoma
Completed NCT00179608 - Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy Phase 1
Terminated NCT00104884 - FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma Phase 2